The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).

[Guest guest]

Blank The prognostic significance of TP53 mutations in Chinese patients with

chronic lymphocytic leukemia is independent of del(17p13).

HJ Dong, LT Zhou, DX Zhu, DM Wang, C Fang, HY Zhu, Y Zhuang, KR Miao, W Xu, and

JY Li

Ann Hematol, November 27, 2010; .

Department of Hematology, The First Affiliated Hospital of Nanjing Medical

University, Jiangsu Province Hospital, Nanjing, 210029, China.

The poor prognosis of chronic lymphocytic leukemia (CLL) patients with

del(17p13) is well established. Several studies have shown that cases with TP53

mutations and TP53 mutations without del(17p13) may be adverse prognostic

factors. We studied 173 well-characterized CLL patients by direct sequencing to

detect TP53 mutations (exons 2-11). TP53 mutations were detected in 14.5% (25 of

173) of samples. Most patients with del(17p13) had TP53 mutations (72.2%).

Mutations in the absence of del(17p13) were found in 8.3% in our cohort, which

were higher than other countries. Compared with cases without TP53 alterations,

TP53 mutations and deletions were both associated with advanced stages and

unmutated immunoglobulin heavy-chain variable region status. Survival analysis

showed that the occurrence of TP53 mutations and del(17p13) were associated with

shorter overall survival (OS), treatment-free survival (TFS), and resistance to

chemotherapy. TP53 mutations were the variables strongly associated with OS and

TFS by multivariate regression analysis. Moreover, we also found that cases

with TP53 mutations in the absence of del(17p13) had a similar clinical and

biological course and similar poor short OS as cases carrying del(17p13) in

Chinese patients with CLL.

PMID: 21113594